Today's Must Read
Morgan Stanley (MS) Q2 Earnings Depict Trading Weakness
Union Pacific (UNP) Q2 Earnings in Line; Coal Woes Linger
Monday, August 01, 2016
In today's Research Daily write-up, we are featuring updated research reports on 16 stocks, including AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP). These reports were picked from the roughly 80 research reports issued by our analyst team today.
AbbVie’s strong Q2 results and positive guidance should help sustain the stock's recent favorable momentum. The analyst likes its flagship product Humira’s performance and thinks sales will continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. The Pharmacyclics acquisition has diversified AbbVie’s presence and should also boost long-term growth. (You can read the full research report on ABBV here.)
Morgan Stanley shares have reversed some of the earlier weakness following the strong June quarter report, but the pure-play brokerage firm lacks a near-term catalyst. The analyst is encouraged by the approval of its capital plan and strategic plans to improve profitability. The company has also significantly diversified its footprint and product portfolio. (You can read the full research report on MS here.)
Union Pacific shares have been strong performers lately, but the outlook for the railroad operator continues to remain challenging. This became obvious in the company's mixed June quarter earnings report. Apart from coal, decreasing volumes of industrial products, agricultural products, automotive, chemicals and intermodal led to the decline. However, the analyst likes the company's efforts to reward shareholders through dividends and share buybacks. (You can read the full research report on UNP here.)
You can find all of today's stock research reports here >>>
Free Access: All Zacks Research Reports Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, please click here >>